Fresh Agent Reduces Month-to-month Migraine Days

—
Investigational Lu AG09222 met foremost pause point in proof-of-thought trial

by
Judy George, Deputy Managing Editor, MedPage This day

September 4, 2024

A monoclonal antibody focused on a recent migraine prevention pathway confirmed success in the part II HOPE trial.

A single 750 mg intravenous infusion of investigational Lu AG09222 bested placebo in reducing migraine frequency over the subsequent 4 weeks, reported Messoud Ashina, MD, of Copenhagen University Clinic–Rigshospitalet in Denmark, and co-authors.

At baseline, the mean sequence of month-to-month migraine days became 16.7. Thru week 4, the Lu AG09222 neighborhood had 6.2 fewer month-to-month migraine days, while the placebo neighborhood had 4.2 fewer days (distinction, -2.0 days, 95% CI -3.8 to -0.3, P=0.02).

Lu AG09222 targets pituitary adenylate cyclase-activating polypeptide (PACAP), a vasodilating polypeptide thought be fascinating by migraine pathophysiology.

“These findings train the proof of thought, showing that inhibition of PACAP signaling by Lu AG09222 represents a brand new and doubtlessly effective mechanism for migraine prevention,” Ashina and colleagues wrote in the Fresh England Journal of Remedy.

Early experiments reported that intravenous infusion of PACAP resulted in migraine assaults in migraine sufferers. A part I notion of wholesome volunteers confirmed that Lu AG09222 inhibited PACAP-resulted in cranial artery dilation and lowered concomitant headache.

If Lu AG09222 in a roundabout scheme is accredited by the FDA, this is in a position to maybe be the 2d class of monoclonal antibody therapies for migraine prevention — the first being antibodies to calcitonin gene-connected peptide (CGRP) or its receptor, eminent Elizabeth Loder, MD, MPH, of Brigham and Ladies folk’s Clinic in Boston, in an accompanying editorial.

“Despite the indisputable fact that warning is useful when results across trials are in comparison, the modest between-neighborhood distinction of two migraine days per month noticed in the present trial is the same to the outcomes of trials of the CGRP monoclonal antibodies and lower than the distinction noticed with some established non-antibody preventive therapies for migraine, equivalent to onabotulinum toxin A or topiramate,” Loder pointed out.

“Even when a brand new PACAP antibody is no longer more effective than existing therapies, its arrival is silent purposeful,” she added. “It’s miles continually factual news when one more doubtless target for migraine is identified and proves amenable to remedy.”

HOPE enrolled 237 sufferers with episodic or power migraine who had failed two to four outdated preventive therapies. Contributors had been randomly assigned to obtain a single-dose baseline infusion of 750 mg or 100 mg of LuAG09222 or placebo. Overall, 97 members purchased 750 mg LuAG09222, 46 purchased 100 mg, and 94 purchased placebo.

Baseline traits had been on the total identical across the three trial groups. Indicate age became 42.5 years, 100% of members had been white, and 88% had been girls.

The notion incorporated a 4-week remedy length and eight weeks of apply-up. The essential pause point became the mean alternate from baseline in the sequence of month-to-month migraine days in the future of weeks 1 thru 4 in the 750-mg neighborhood versus placebo. Contributors performed a every day digital diary to cling headache occasions, symptoms, and other files.

Within the 4-week remedy length, the percentage of members who had a reduction from baseline of at least 50% in the sequence of month-to-month migraine days became 32% in the 750-mg neighborhood and 27% in the placebo neighborhood.

Opposed occasions with a increased incidence in the remedy neighborhood versus the placebo neighborhood over 12 weeks incorporated COVID-19 (7% vs 3%), nasopharyngitis (7% vs 4%), and fatigue (5% vs 1%).

There became one serious opposed tournament in the 750-mg neighborhood, identified as sympathetic posterior cervical syndrome, which became reported 1 month after the infusion. The participant had a ancient past of vertebrogenic effort syndrome, and the tournament became deemed to be unrelated to Lu AG09222 remedy.

The notion had several boundaries, Ashina and co-authors acknowledged. “As a proof-of-thought trial, the sample size became cramped, the trial became immediate in length and apply-up, and members purchased handiest one dose of Lu AG09222,” they wrote. Migraine sufferers with clinically foremost cardiovascular illness or other confounding health concerns had been excluded and findings couldn’t be indicative of efficacy or safety in all migraine sufferers.

On myth of PACAP would possibly maybe play a foremost role in reducing neuroinflammation or ischemia, its safety when faded along with other therapies will need scrutiny, along with higher characterization of its ends in pregnancy, Loder eminent. “The latter is largely important for the rationale that majority of sufferers who obtain remedy for migraine are girls of childbearing age,” she wrote.